BioSpace

OCTOBER 14, 2021

Read about TFF Pharmaceuticals and Augmenta Bioworks' dry powder COVID-19 antibody formula, the world's first gene editing clinical trial for PKU, Bayer's COVID-19 vaccine and other key developments in life sciences research.

Gene Editing 87

Gene Editing Life Science Clinical Trials Clinical Trials 87

BioSpace

NOVEMBER 15, 2021

This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.

Gene Editing 75

Gene Editing Life Science Genome Genomics 75

XTalks

OCTOBER 12, 2021

Last week, a study that “stumbled upon” a vaccine for rheumatoid arthritis (RA) was published in the Proceedings of the National Academy of Sciences. The vaccine was tested in rats and showed strong, immediate and long-lasting immune responses to confer protection against the disease. With the finding that 14-3-3?

Vaccination 105

Vaccination Vaccine Research Immune Response 105

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. BacTRL Gene Therapy Platform.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

Pharmaceutical Technology

NOVEMBER 23, 2022

One of the primary focus areas includes the continued commercialisation of cutting-edge cell and gene therapies, which involve the modification of cells from patients or donors to produce highly personalised therapies and regenerative medicines. OmniaBio scales CDMO operations in Hamilton.

Marketing 130

Marketing Gene Therapy Life Science Manufacturing 130

Drug Discovery World

SEPTEMBER 20, 2023

The ‘ Scottish Advanced Therapy Medicinal Products (ATMP) and Vaccines Network ’ specifically targets researchers in the north of the UK and will coordinate events, talks from industry leaders and networking opportunities for the advanced therapies industry.

Life Science 110

Life Science Gene Therapy Gene Vaccination 110

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

XTalks

APRIL 26, 2021

After years of disappointing malaria vaccine trials, a malaria shot developed by researchers at the Jenner Institute at the University of Oxford has demonstrated an unprecedentedly high efficacy of 77 percent, and may be the magic bullet the world has been waiting for against the deadly disease.

Vaccination 105

Vaccination Vaccine Immune Response Trials 105

Drug Discovery World

MAY 6, 2024

Thanks to a prestigious academic legacy, Europe has long been a dominant region for life sciences. Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany.

Drugs 59

Drugs Life Science Gene Editing Gene 59

pharmaphorum

JULY 6, 2021

The new figures – from the BioIndustry Association and Clarivate – were dominated by more than £1 billion in venture capital funding for UK biotech and life sciences companies, headlined by DNA sequencing company Oxford Nanopore’s £195 million raise in May that was just shy of the £205 million record set by Immunocore in 2005.

Life Science 141

Life Science Gene Therapy DNA Gene 141

XTalks

SEPTEMBER 12, 2023

Life science podcasts have emerged as an invaluable tool for building connections with audiences in the digital era. Furthermore, we’ll explore the unique advertising opportunities that this platform offers, positioning brands at the forefront of the life science industry. The result?

Life Science 105

Life Science Branding Clinical Trials Clinical Trials 105

Drug Discovery World

MAY 24, 2023

IB Communications’ CEO Michelle Boxall explains why there are two sides to the cell and gene therapy coin. That said, the life science sector does run on differing investment cycles to other industries and success will still generate rewards in 2023. Budgets are being scrutinised. There’s less room for grey areas.

Gene Therapy 52

Gene Therapy Life Science Gene Sales 52

The Pharma Data

JANUARY 12, 2021

In December, life sciences giant Bayer launched a cell and gene therapy platform within its pharmaceutical division in order to become a leading company within a rapidly emerging and evolving field that offers the potential of life-saving therapies. Photo courtesy of Bayer. The platform is already bearing fruit.

Gene Therapy 52

Gene Therapy Gene Gene Editing Licensing 52

The Pharma Data

OCTOBER 26, 2020

The agreement covers the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein. Sensorion is currently advancing two preclinical gene therapy programs conducted under a broad multi-program research partnership with the Genetics and Physiology of Hearing Unit at Institut Pasteur (Paris).

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

pharmaphorum

DECEMBER 22, 2020

With funding from the government-backed Cell and Gene Therapy Catapult , the centres bring with them complementing capabilities and a vast wealth of experience across manufacturing and bioprocessing.

Gene Therapy 70

Gene Therapy Manufacturing Gene Vaccination 70

Drug Discovery World

NOVEMBER 27, 2023

By Anis H Khimani , PhD, Senior Strategy Leader, Life Sciences strategy group, Revvity, Inc. Upstream cell line development has seen notable progress with recent advances in cell line engineering, particularly in enhancing gene of interest integration specificity, clone selection, and production efficiency.

Production 59

Production Engineer Gene Editing Gene 59

Pharmaceutical Technology

MAY 15, 2023

A major strategy for OV development is genetic manipulation to weaken virus pathogenicity, enhance target selectivity, reduce adverse reactions, and/or insert exogenous therapeutic genes into the virus genome. Akamis Bio, formerly PsiOxus Therapeutics, develops and discovers therapies for the treatment of cancer and other related diseases.

Protein 130

Protein Gene Genetics Gene Therapy 130

Pharmaceutical Technology

APRIL 18, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These can serve as an important component of a vaccine.

Protein 147

Protein Vaccination Vaccine Production 147

Drug Discovery World

APRIL 27, 2023

The report notes that the focus on science and pharma throughout the Covid-19 pandemic has resulted in the emergence of new locations as life science hubs and name checks Boston, Massachusetts and San Francisco, California as examples of centres with heightened investment appeal in the life sciences 1.

Life Science 52

Life Science Drugs Research Gene Splicing 52

XTalks

NOVEMBER 30, 2023

More Investigational Therapies for HIV Are on the Way American Gene Technologies, a pioneering biotech company headquartered in Rockville, Maryland, has released promising results from its Phase I trial of AGT103-T, a gene therapy designed for individuals with chronic HIV disease. In November 2023, Hookipa Pharma Inc.,

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

FEBRUARY 22, 2021

State Premier of North Rhine-Westphalia Armin Laschet and Birgitta Radermacher, President of Duesseldorf Administrative District, today visited Bayer AG’s research and production site in Wuppertal to gain an insight into the planned vaccine production there. Effective vaccines are our best weapon to combat the pandemic. About Bayer.

Production 40

Production Vaccination Vaccine Gene Therapy 40

Drug Discovery World

DECEMBER 20, 2022

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. In summary, 2023 could be a very exciting year for life sciences. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023. .

Drugs 52

Drugs Gene Editing Clinical Trials Clinical Trials 52

Pharma Marketing Network

MARCH 2, 2022

.” IQVIA measures its success of novel molecules in clinical trials by clinical development productivity, which experienced a decline across all disease areas in 2021, except for, of course, vaccines and in cardiovascular. More than 3,000 life sciences companies are involved in R&D work.

Drugs 52

Drugs Life Science Production Gene Therapy 52

Drug Discovery World

MARCH 13, 2024

With government support and strong academic institutions, does Singapore have what it takes to become a global centre for life sciences? DDW’s Diana Spencer explores how the country is turning pioneering science into a successful biotech industry. We are now working at ways to target TOX2 including use of PROTAC to degrade TOX2.

Life Science 69

Life Science Genome Genomics Research 69

pharmaphorum

OCTOBER 26, 2021

Once a staunch devotee of the diversified life sciences business model, Novartis has been steadily trimming down its focus in recent years, cashing in non-core business to generate billions of dollars and reinvesting the proceeds in its pharma R&D pipeline.

Sales 115

Sales Gene Therapy Life Science Medicine 115

Pharma Marketing Network

MARCH 2, 2022

.” IQVIA measures its success of novel molecules in clinical trials by clinical development productivity, which experienced a decline across all disease areas in 2021, except for, of course, vaccines and in cardiovascular. >3,000 life sciences companies are involved in R&D work. IQVIA’s Report Highlights.

Drugs 52

Drugs Life Science Production Gene Therapy 52

XTalks

DECEMBER 22, 2021

If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the life sciences. Here is a look at some life science trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.

Life Science 98

Life Science RNA Vaccination Vaccine 98

XTalks

MARCH 25, 2021

Xtalks is proud to announce the launch of the Xtalks Life Science podcast. Subscribe to the Xtalks Life Science Podcast to never miss a new episode. Fresh Conversations About Life Science Topics. She focuses on news relating to the food industry and writes blogs on recruitment and HR in the life sciences.

Life Science 105

Life Science HR Clinical Trials Clinical Trials 105

XTalks

DECEMBER 1, 2021

Moreover, it is also not known how the current COVID-19 vaccines and drugs will hold up against Omicron. The S gene that encodes the characteristic protein harbors a deletion mutation (69-70del), which was also identified in the Alpha variant. the severity of disease) and potential for immune evasion of Omicron.

Gene 105

Gene Genome Genomics Genetics 105

Drug Discovery World

OCTOBER 4, 2022

Taking place at the ExCel in London from 4-5 October, ELRIG Drug Discovery 2022 is set to provide visitors with access to the latest trends, technologies and expertise driving the life sciences sector. . Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7 billion, compared to $19.9

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

XTalks

OCTOBER 18, 2022

Read on to learn why life science and clinical research professionals are choosing a career with Medpace. Being a scientifically-driven and therapeutically aligned CRO, candidates can put their life-science backgrounds to work in a broad range of positions across a range of therapeutic and specialty areas. Cardiovascular.

Clinical Research 111

Clinical Research Research Clinical Trials Clinical Trials 111

The Pharma Data

JANUARY 5, 2021

Over the past several weeks, Helix has analyzed recent positive samples and identified those with ‘S gene dropout’ on their diagnostic PCR assay, indicating the potential presence of the emerging B1.1.7 Illumina then sequenced a subset of these ‘S gene dropout’ samples using Illumina’s COVIDSeq Test, which identified the B.1.1.7

Genome 52

Genome Genomics Life Science Development 52

Drug Discovery World

NOVEMBER 1, 2022

The Sector Snapshot 2022 was commissioned by AusBiotech, an Australian industry body representing and advocating for organisations doing business in and with the global life sciences economy 1. Another key figure outlined by AusBiotech is that Victoria and New South Wales are home to 73% of the life science sector.

Drugs 52

Drugs Life Science Research Genome 52

XTalks

MAY 2, 2024

Moderna’s RSV Vaccine Maker: Moderna PDUFA: May 12, 2024 Estimated 2028 revenue: $913 million After GSK won the first ever FDA approval for an RSV vaccine with Arexvy , closely followed by approval of Pfizer’s RSV shot Abrysvo last year, Moderna isn’t too far behind with its RSV vaccine. percent to 77.8 percent in year two.

Drugs 52

Drugs FDA Approval Sales Vaccination 52

XTalks

APRIL 24, 2024

ImmunityBio’s Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) along with the Bacillus Calmette-Guérin (BCG) vaccine has won US Food and Drug Administration (FDA) approval for the treatment of non-muscle invasive bladder cancer (NMIBC). Anktiva is mixed together with the BCG vaccine before administration.

FDA Approval 52

FDA Approval Vaccination Vaccine Sales 52

pharmaphorum

NOVEMBER 23, 2022

A director in life sciences consulting for EY, she works within the commercial space for such companies, as well as their clients. “My We looked at the areas of rare diseases, cell and gene therapy, vaccines – loads of different perspectives. Innovative offerings around market access. Smart reviewing: utilising AI and ML.

Life Science 98

Life Science Marketing Medicine Production 98

XTalks

DECEMBER 12, 2023

PNH is caused by a mutation in the CFB gene that codes for complement factor B, a component of the alternative pathway of complement activation. Mutations in the gene result in the production of red blood cells that are prone to premature destruction (hemolysis).

FDA Approval 95

FDA Approval Bacteria Trials Protein 95